SHAREHOLDER ALERT: Investigation of Immunovant Announced by Holzer & Holzer, LLC
February 02, 2021 12:32 PM EST | Source: Holzer & Holzer LLC
Atlanta, Georgia--(Newsfile Corp. - February 2, 2021) - Holzer & Holzer, LLC is investigating whether Immunovant, Inc. (NASDAQ: IMVT) ("Immunovant" or the "Company") complied with federal securities laws. On February 2, 2021, the Company announced it had decided to voluntarily pause dosing in ongoing clinical studies in both Thyroid Eye Disease and Warm Autoimmune Hemolytic Anemia after it had "become aware of a physiological signal consisting of elevated total cholesterol and LDL levels in IMVT-1401-treated patients." The price of Immunovant's stock fell following the announcement.
If you purchased shares of Immunovant and suffered a loss on that investment, you are encouraged to contact Corey D. Holzer, Esq. at cholzer@holzerlaw.com or Luke R. Kennedy, Esq. at lkennedy@holzerlaw.com, or by toll-free telephone at (888) 508-6832 to discuss your legal rights or at www.holzerlaw.com.
Holzer & Holzer, LLC is an Atlanta, Georgia law firm that dedicates its practice to vigorous representation of shareholders and investors in litigation nationwide, including shareholder class action and derivative litigation. Since its founding in 2000, Holzer & Holzer attorneys have played critical roles in recovering hundreds of millions of dollars for shareholders victimized by fraud and other corporate misconduct. More information about the firm is available through its website, www.holzerlaw.com and upon request from the firm. Holzer & Holzer, LLC has paid for the dissemination of this promotional communication, and Corey D. Holzer is the attorney responsible for its content.
CONTACT:
Corey D. Holzer, Esq.
(888) 508-6832 (toll-free)
cholzer@holzerlaw.com
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/73458